**Core Concept**
The question is testing the student's understanding of prenatal screening tests used to detect neural tube defects (NTDs) and ventral wall defects in fetuses. The correct answer involves a specific marker in maternal serum that can help differentiate between these two types of defects.

**Why the Correct Answer is Right**
Alpha-fetoprotein (AFP) is a protein produced by the yolk sac and fetal liver. In cases of open neural tube defects, such as spina bifida, AFP levels are typically elevated in maternal serum due to the exposure of the neural tissue to the amniotic fluid. However, in ventral wall defects, such as omphalocele, AFP levels are usually decreased because the defect allows AFP to escape into the amniotic fluid. The acetylcholinesterase (AChE) test can also be used, but the most useful test in distinguishing between open NTDs and ventral wall defects is the AFP level. The ratio of AFP to human chorionic gonadotropin (hCG) is also used, but the most specific marker is the AFP level itself.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it is not a specific marker for distinguishing between open NTDs and ventral wall defects.
* **Option B:** This option is incorrect because the AChE test is used to detect the presence of AChE in the amniotic fluid, which is a marker for open neural tube defects, but it is not the most useful test in distinguishing between open NTDs and ventral wall defects.
* **Option C:** This option is incorrect because the triple screen test (AFP, hCG, and estriol) is a general screening test for Down syndrome and other fetal anomalies, but it is not specific for distinguishing between open NTDs and ventral wall defects.

**Clinical Pearl / High-Yield Fact**
In cases of elevated AFP levels in maternal serum, it is essential to perform a targeted ultrasound to confirm the presence of an open neural tube defect or a ventral wall defect.

**Correct Answer:** C.